Association of HLA-B38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients

Table 4

Comparison of clinical severity between HLA-B38:02 carriers and HLA-B38:02 noncarriers.

Characteristic	HLA-B38:02		value
	Positive ()	Negative ()
Age (yr); Mean (SD)	43.1 (13.1)	42.4 (8.2)	0.89
Male to female ratio	1 : 10	0 : 10
Antithyroid drug, N (%)
PTU (mg/d)	0 (0)	2 (20)
MMI (mg/d)	11 (100)	8 (80)
Dose of ATD at the time of recruitment; Mean (SD)
PTU (mg/d)	n/a	250 (70.7)
MMI (mg/d)	21.8 (6.8)	20.0 (4.6)
Mean granulocytes at the time of recruitment (cell/μL); Mean (SD)	162.7 (156.3)	178 (175.1)	0.83
Thyroid hormone at the time of recruitment; Median (Q1–Q3)			0.2
FT3 (pg/mL)	6.7 (2.5–11.4)	5.9 (4.3–19.6)	0.5
FT4 (pg/mL)	32.6 (14.5–62.8)	37.2 (19.7–80.3)	0.6
TSH (mIU/L)	0.01 (0.004–0.01)	0.018 (0.004–0.017)
Recover period (day); Median (Q1–Q3)	7 (4.5–7.5)	3 (3–5)	0.7
Death, N (%)	2 (18.2)	0 (0)	n/a

ATD: antithyroid drug; PTU: propylthiouracil; MMI: methimazole.